Extension of Share Purchase Plan

MELBOURNE Australia, 15 September 2026 – Prescient Therapeutics (ASX: PTX) (**PTX** or the **Company**), a clinical-stage oncology company developing targeted cancer therapies, advises that the closing date for the Share Purchase Plan (SPP) announced to the market on 25 August 2026 has been extended from 5.00pm (AEST) on Tuesday, 15 September 2026 to 5.00pm (AEST) on Friday, 18 September 2026.

The extension has been made to provide eligible shareholders with additional time to participate in the SPP following requests from shareholders who experienced delays in receiving the SPP documentation.

The Board is encouraged by shareholder participation to date and notes that all eligible directors have participated in the SPP.

Under the SPP new fully paid ordinary shares will be issued at $0.065 per share, representing an 18.8% discount to the volume weighted average price (VWAP) over the 10 trading days before the date the SPP was announced.

Eligible Shareholders who were registered holders of Shares at 7.00pm (AEST) on 24 August 2026 (Record Date) may apply for up to A$30,000 of new fully paid ordinary shares (New Shares) in the Company under the SPP.

An updated timetable with the new closing date for the SPP is as follows:

Event	Indicative Date
Record Date	7.00pm (Sydney time) on Monday, 24 August 2026
Announcement of SPP Offer and lodgement of Appendix 3B	Tuesday, 25 August 2026
SPP Opens	Wednesday, 26 August 2026

Dispatch of Personalised SPP Application Form (and accompanying mail out letters)	Thursday, 27 August 2026
Revised SPP Closes	5.00pm (AEST) on Friday, 18 September 2026
Revised SPP results announced to the ASX	Thursday, 24 September 2026
Revised Issue of Shares under SPP	Friday, 25 September 2026
Revised Trading of all SPP Shares (subject to ASX listing rules)	Monday, 28 September 2026
Revised Dispatch of holding statements to Eligible Shareholders participating in the SPP	Tuesday, 6 October 2026

In accordance with the instructions in the SPP booklet and on the personalised Application Form, Eligible Shareholders may apply using BPAY or by completing the Application Form and returning it to Prescient's share registry together with payment via Electronic Funds Transfer order by 5.00pm (Sydney time) on Friday, 18 September 2026.

Participate in the Share Purchase Plan

Shareholders can request an electronic copy of their personalised Share Purchase Plan application form be emailed to them from the below link:
https://prescienttherapeutics.investorportal.com.au/share-purchase-plan-opportunity-request/

Reach Markets are the advisers managing the Share Purchase Plan and can be contacted on 1300 805 795 or via advisers@reachmarkets.com.au

Join an investor briefing

CEO James McDonnell will be holding an online investor briefing at 11.00am (AEST), Friday, 18 September 2026 where he will discuss the Dose Optimisation Committee review milestone, and why this presents as a significant step toward advancing PTX-100 into the next stage of development.

Register here:https://prescienttherapeutics.investorportal.com.au/investor-briefing/

The Disclosure Committee of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries

James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

Investor & Media enquiries

Patrick Nelson
Reach Markets
1300 805 795
ir@reachmarkets.com.au

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100 is a first-in-class compound with the ability to block an enzyme that can contribute to cancer growth known as geranylgeranyl transferase-1 (GGTase-1). Blocking this target disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral signaling circuits in cancer cells, leading to their apoptosis (death). Mutations in Ras pathways are believed to be involved in up to 22% of all cancers.

PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and in a recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T-cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T-Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T-cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the Phase 2a part of the trial.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in preclinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pretreated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Forward Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.